Trials / Completed
CompletedNCT01463891
Post-marketing Surveillance for the Clinical Safety and Effectiveness of Eribulin Mesylate in Patients With Inoperable or Recurrent Breast Cancer (Study HAL01S)
Post-marketing Surveillance for the Clinical Safety and Effectiveness of Eribulin Mesylate in Patients With Inoperable or Recurrent Breast Cancer
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 963 (actual)
- Sponsor
- Eisai Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
To investigate of the clinical safety and effectiveness of eribulin mesylate in patients with inoperable or recurrent breast cancer
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Eribulin Mesylate | The usual adult dose of eribulin mesylate is 1.4 mg/m\^2 (body surface area) administered intravenously over 2 to 5 minutes, once daily once a week. Treatment shall be continued for 2 consecutive weeks followed by a third week of drug cessation. With each cycle lasting 3 weeks, the treatment shall be repeated. The dose may be reduced, depending on the condition of the individual patient. |
Timeline
- Start date
- 2011-07-19
- Primary completion
- 2012-12-26
- Completion
- 2013-11-27
- First posted
- 2011-11-02
- Last updated
- 2023-07-24
Locations
223 sites across 1 country: Japan
Source: ClinicalTrials.gov record NCT01463891. Inclusion in this directory is not an endorsement.